API
< Back to situation

[REVISION HISTORY]

Sildenafil shows anti‑metastatic promise

13 recorded revisions of this situation.

What changed

2026-08-07 18:28 UTC → 2026-08-09 23:22 UTC · added removed

Late July 2026 pre‑clinical work from U.S. and Israeli labs showed that sildenafil, the active ingredient of Viagra, blocks PDE5, raises cGMP, and sequesters cholesterol in lysosomes, suppressing metastatic spread in mouse models of breast, lung, colon and prostate cancer. The July 22 report detailed the same cholesterol‑dependent mechanism and noted that co‑administration with statins further reduced tumor‑cell migration. Analyses of Israeli health‑service records covering nearly five million patients found improved survival among cancer patients prescribed sildenafil, especially when combined with statins. A July 30 study in *Cancer Research* by Ayelet Erez and Yarden Ariav described the PDE5‑cGMP‑NPC1 pathway and confirmed the retrospective survival benefit. Follow‑up papers on July 31 and August 1 reiterated the mechanistic findings and emphasized that the National Cancer Institute views the repurposing approach as promising but experimental, warning against self‑medication. On August 3, a further pre‑clinical report from the Weizmann Institute and the U.S. National Cancer Institute reaffirmed these results, showing marked reductions in metastasis formation, especially when combined with statins. On August 6, a new *Cancer Research* article by the same collaborative team expanded the preclinical evidence, highlighting the strongest anti‑metastatic signals in breast, melanoma and lung cancers and announcing plans for clinical trials, particularly in triple‑negative breast cancer. The same day, researchers at the Weizmann Institute reported that sildenafil blocked cholesterol transport into tumor cells, reducing movement of human breast, lung and colon cancer cells, with the greatest effect in triple‑negative breast cancer. In mouse models, tumor spread to the lungs fell by more than 50 %. 50%. A two‑decade two-decade analysis of about five million Clalit health‑system health-system records showed a 26 % 26% lower five‑year five-year mortality risk for cancer patients using sildenafil, an effect amplified when patients also used statins. These findings reinforce the move toward clinical trials in women with triple‑negative breast cancer.

Versions

  1. 2026-08-09 23:22 UTC Sildenafil shows anti‑metastatic promise
  2. 2026-08-07 18:28 UTC Sildenafil shows anti‑metastatic promise
  3. 2026-08-07 04:14 UTC Sildenafil shows anti‑metastatic promise
  4. 2026-08-06 07:45 UTC Sildenafil shows anti‑metastatic promise
  5. 2026-08-05 18:12 UTC Sildenafil shows anti‑metastatic promise
  6. 2026-08-04 13:23 UTC Sildenafil shows anti‑metastatic promise
  7. 2026-08-03 17:16 UTC Sildenafil shows anti‑metastatic promise
  8. 2026-08-03 13:39 UTC Sildenafil shows anti‑metastatic promise
  9. 2026-08-01 20:54 UTC Sildenafil potential to inhibit cancer metastasis
  10. 2026-07-31 22:04 UTC Sildenafil potential to inhibit cancer metastasis
  11. 2026-07-31 17:35 UTC Sildenafil potential to inhibit cancer metastasis
  12. 2026-07-31 13:54 UTC Sildenafil potential to inhibit cancer metastasis
  13. 2026-07-27 20:47 UTC Sildenafil potential to inhibit cancer metastasis
  14. 2026-07-25 21:43 UTC Sildenafil potential to inhibit cancer metastasis

Select a version to see what changed compared to the one before it.